3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
83
Metastatic Castration Resistant Prostate Cancer
9
Breast Neoplasms
9
Neoplasms
8
Neoplasm Metastasis
8
Prostatic Neoplasms, Castration-Resistant
6
Prostate Cancer Metastatic
4
Castration-resistant Prostate Cancer
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Triple Negative Breast Neoplasms
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-resistant Prostate Cancer
2
Metastatic Castration-Resistant Prostate Cancer
2
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Urinary Bladder Diseases
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Ureteral Diseases
1
Seizures
1
Recurrent Endometrial Endometrioid Adenocarcinoma
1
Prostate Carcinoma Metastatic to the Bone
1
Primary Dysautonomias
1
Primary Breast Cancer ER+ve
1
Pharmacokinetics of MDV3100
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Non-metastatic, Hormone naïve Prostate Cancer
1
Non-metastatic Prostate Cancer
1
Metastatic Progressive Castration-resistant Prostate Cancer
1
Interventions
Cancer Vaccines
2
Adjuvants, Immunologic
2
veliparib
1
glutathione pegylated liposomal doxorubicin
1
enzalutamide
1
Trastuzumab
1
Radiosurgery
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Brain Diseases
×
enzalutamide
×
Clear all
NCT04290611
2023-04-13
VENDY
Groupe Hospitalier Pitie-Salpetriere
Completed
500,000 enrolled